Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 2,637 Shares

Key Points

• Hims & Hers Health insider Soleil Boughton sold 2,637 shares at an average price of $58.79, totaling approximately $155,029, reducing their ownership by 1.58%.
• The stock price of Hims & Hers Health has experienced a 4.1% decline, trading at $56.71, with a market cap of about $12.82 billion.
• Despite reporting a missed earnings estimate for the previous quarter, with $0.17 EPS compared to the forecasted $0.18, the company's revenue increased 72.6% year-over-year.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,637 shares of Hims & Hers Health stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $58.79, for a total value of $155,029.23. Following the sale, the insider directly owned 163,767 shares in the company, valued at approximately $9,627,861.93. The trade was a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 17th, Soleil Boughton sold 2,637 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.50, for a total transaction of $133,168.50.
• On Monday, August 25th, Soleil Boughton sold 2,571 shares of Hims & Hers Health stock. The shares were sold at an average price of $44.53, for a total transaction of $114,486.63.
• On Monday, August 11th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $51.64, for a total transaction of $132,818.08.
• On Monday, July 28th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.70, for a total transaction of $150,976.40.
• On Monday, July 14th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $47.82, for a total transaction of $122,993.04.

Hims & Hers Health Stock Down 4.1%

Shares of HIMS stock traded down $2.41 during trading hours on Tuesday, hitting $56.71. 20,717,295 shares of the company's stock traded hands, compared to its average volume of 32,827,969. The stock's fifty day simple moving average is $51.45 and its two-hundred day simple moving average is $46.72. Hims & Hers Health, Inc. has a 12-month low of $16.05 and a 12-month high of $72.98. The stock has a market cap of $12.82 billion, a price-to-earnings ratio of 70.89, a PEG ratio of 3.94 and a beta of 2.14. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. During the same quarter in the previous year, the business posted $0.06 earnings per share. Hims & Hers Health's revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in HIMS. Virtus Advisers LLC purchased a new stake in Hims & Hers Health during the 2nd quarter valued at $26,000. Quaker Wealth Management LLC purchased a new stake in Hims & Hers Health during the 2nd quarter valued at $29,000. Bessemer Group Inc. raised its stake in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after buying an additional 312 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health during the 1st quarter valued at $30,000. Finally, Skandinaviska Enskilda Banken AB publ raised its stake in Hims & Hers Health by 408.2% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock valued at $37,000 after buying an additional 600 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a report on Monday, June 23rd. Zacks Research lowered shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Morgan Stanley restated an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Finally, Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Reduce" and a consensus target price of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.